Allara raised $10 million in a Series A funding round led by GV. The startup offers membership-based virtual services to treat women's chronic hormonal conditions, such as PCOS and endometriosis. CEO Rachel Blank — former executive at Ro and investor at General Catalyst — founded the company partly due to the difficulty she experienced arriving at her own PCOS diagnosis.
Armed with fresh capital, Nava Benefits hopes to take advantage of what it believes will be a disruption in the way smaller businesses approach health and wellness benefits, including the many digital tools now on the market.
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
According to a CB Insight's report, GV (formerly Google Ventures) funded the most digital health companies with 22 investments, making it most active investor in that sector for four years in a row.
The Boston-based company plans to develop small-molecule therapeutics that go after historically "undruggable" targets using a process known as protein degradation.
Owkin, a startup building a decentralized health research platform, rounded out its series A round with another $18 million in funding. It uses federated learning to allow researchers to collaborate on AI models while keeping data onsite.
The co-founders of the company include Hans Bishop, who founded Juno Therapeutics - one of the earliest commercial developers of CAR-T cell therapy technology - in 2013.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
The San Francisco-based startup is one of several that have been raising money over the past couple of weeks in areas like neurology, oncology and women's health.
After Miki Kapoor joined Verana Health in 2018, the company shifted from a tele-ophthalmology startup to a data analytics company. Since then, Verana has raised $100 million in funding led by GV and made its first major acquisition.
GV, formerly known as Google Ventures, led a $100 million funding round in Verana Health. The San Francisco-based company aggregates clinical data for medical research and analytics.
The startup, founded by a prominent health policy expert and a biotech industry executive, aims to bring down the cost of drugs by re-engineering and making less costly the process by which they are discovered and brought to patients.
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
The company, led by a Gilead Sciences veteran, plans to use the platform to find drugs that go after "undruggable" targets.
The company, partnered with Beam Therapeutics, Verily Life Sciences and academic institutions, plans to use gene editing to tackle coronary artery disease. However, experience with gene therapy indicates cost could be a hurdle.
The company has raised more than $100 million since 2017 and plans to use the current funding to build a pipeline of RNA-targeting small molecules.
The company is developing means using CRISPR/Cas9 to edit genomes at the single-letter level, as opposed to the DNA- and RNA-cutting method usually employed.
Third Rock and ARCH led the launch of the company, which will look at ways to target genetic modifiers that can protect against certain diseases.